Compare Novo Nordisk A/S (NVO) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tenet Healthcare Corporation — how do they compare? Novo Nordisk A/S trades at $49.36 (market cap $220.53B), while Tenet Healthcare Corporation trades at $196.03 (market cap $16.74B). The key difference: Novo Nordisk A/S is far larger — about 13.2× Tenet Healthcare Corporation's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| NVO | THC | |
|---|---|---|
Market Cap | $220.53B | $16.74B |
Sector | Health | Health |
52-Week High | $71.70 | $244.80 |
52-Week Low | $35.29 | $148.38 |
Enterprise Value | $239.49B | $26.99B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten EPS estimates for three consecutive quarters, with a Q2 2026 report due July 24. Valuation metrics appear attractive with a P/E of 10.11 and P/S of 0.79. Revenue and net income are projected to grow in 2026, supported by expansion in outpatient care.
The outlook is positive given analyst consensus with 81% buy ratings and a $234.63 price target, implying 21% upside. Risks include potential pressure from lower patient days and high debt levels. Earnings growth and ambulatory care performance remain key catalysts for near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
